High-dose chemotherapy (HDC) followed by reinfusion of cryopreserved autologous PBSC or, less frequently, bone marrowderived stem cells (BMDSC) is used in the treatment of several pediatric malignancies. In September 2013, a series of six patients undergoing HDC with autologous PBSC rescue at Great Ormond Street Hospital (GOSH), London, who experienced significantly delayed count recovery, was identified. Two additional patients who received cryopreserved allogeneic BMDSC and experienced delayed marrow reconstitution were also identified. This led to the declaration of a Serious Incident and an extensive investigation into the transplant processes in place at GOSH.
1,2 Ultimately a problem with cryopreservation was identified and a revised process established. Retrospective review showed a significant number of patients with delayed neutrophil recovery over many years. However, without a robust system for the data collection, real-time analysis and benchmarking against other centres these issues with delayed engraftment had not been appreciated. Four of these patients with delayed engraftment died and the cases were referred to HM Coroner, who issued a Prevention of Future Deaths Report requiring NHS England to establish improved governance procedures around pediatric autografts. A National Paediatric Autograft Panel (NPAP) has been established and, under its auspices, a national audit of paediatric autograft activity and the engraftment data was undertaken with the aims of determining current national practice and ensuring that any other centres affected by problems with cryopreservation or other issues were identified; prompt engraftment being the ultimate quality measure for successful cell processing. 3 The data were collected retrospectively for the 3-year period 1 September 2012 to 31 August 2015 (based on the date of stem cell return) from each pediatric oncology principal treatment centre (PTC) in England. There was no specific upper limit on patient age. All procedures involving administration of autologous PBSC/BMDSC following HDC were included (regardless of whether such treatment was myeloablative). Each PBSC/BMDSC reinfusion was recorded as a separate procedure. Neutrophil recovery was defined as the first of three consecutive days of neutrophil count 40.5 × 10 9 /L regardless of G-CSF use, and platelet recovery as the first of three consecutive days of platelet count 420 × 10 9 /L with no platelet transfusion in the preceding 7 days. The data were analysed using Prism (Graphpad Software Inc, La Jolla, CA, USA) to calculate median recovery times and 95% percentiles. Median recovery times at different centres were compared to those of the remaining centres using Mann-Whitney test. Bonferroni correction for multiple comparisons was used to determine statistical significance of calculated P values.
The data returns were obtained from all 15 pediatric oncology PTCs in England. Two PTCs did not undertake stem cell procedures, instead referring patients elsewhere before patients returned for supportive care post cell reinfusion. These patient episodes are captured under the PTC responsible for the autologous stem cell procedure itself. Similarly, for patients who received radioisotope therapy ( 131 I-metaiodobenzylguanadine (mIBG) ± topotecan) at another centre, the episode is captured at the centre responsible for the stem cell procedure.
Over the 3-year audit period, there were 297 procedures involving 248 patients across 13 centres. The median number of procedures per centre was 20, equating to 7 per year (range 4-17). The three largest centres (GOSH, Birmingham and Sheffield) undertook 38% of total procedures. The median patient age at first procedure was 5.9 years (range 4 months-20 years), of whom 56% were male.
The most common diagnosis was neuroblastoma, with 121 patients (49% of the total) undergoing a total of 124 procedures. The majority of these (91%) were with busulfan/melphalan (BuMel) HDC for high-risk neuroblastoma (see Table 1 ). The second major diagnostic group comprised CNS tumours, in particular medulloblastoma/primitive neurectodermal tumour (PNET), atypical teratoid rhaboid tumour (ATRT) and intracranial germ cell tumours (72 patients, 29%). Eleven different conditioning regimens were used for these CNS diagnoses. The combination of cisplatin/cyclophosphamide/VCR was used for 43 procedures in 20 individual patients. Thiotepa alone was used for 29 procedures in 19 patients. The other main diagnoses were Hodgkin and other lymphomas (19 patients, 7.6%); Ewing sarcoma (13; 5.2%) and Wilms' tumour (12, 4.8%).
In nearly all cases, the source of stem cells was peripheral blood, with only 11 procedures (4%) using BMDSCs. Overall median administered CD34 + cell dose was 3.8 × 10
6 /kg (range 0.72-18.8 × 10 6 /kg), ⩾ 3 x10 6 /kg in 75% of procedures. Nineteen procedures (6%) used o 2 × 10 6 /kg, of which 6 (32%) were following therapeutic mIBG for neuroblastoma, which may be non-myeloablative. For patients with high-risk neuroblastoma receiving BuMel, 20 procedures (19%) used the CD34 + cell dose o3 × 10 6 /kg mandated by the current European SIOPEN protocol (HR-NBL-1/SIOPEN). ANC and platelet recovery were not significantly prolonged for these patients although the vast majority (n = 17) received 42 × 10 6 /kg cells. Overall median time to ANC recovery (40.5 × 10 9 /L) regardless of G-CSF usage was 12 days (range 0-103). Recovery within 21 days was achieved in 92 ± 2% of patients and within 30 days in 95 ± 1%. Two patients had recovery time 460 days; one with an unusual leukaemia/histiocytosis and another who was an index case for the initial series with delayed engraftment at GOSH. 1 Median time to platelet recovery (420 × 10 9 /L, transfusion independent) was 24 days (range 0-768); 66 ± 3% within 30 days and 80 ± 3% within 42 days. Of nine cases with recovery 490 days, seven were high-risk neuroblastoma patients treated with BuMel. Five patients (2%) died from toxicity prior to bone marrow recovery: two from multi-organ failure, one pulmonary haemorrhage, one adenovirus pneumonia and one busulfan lung toxicity. The audit did not collect the data on transplant-related mortality of patients post engraftment.
Median neutrophil engraftment for the 11 procedures using BM-derived stem cells was significantly longer than those using PBSCs (25 days vs 12 days, P o 0.0001). A similar, albeit non-significant, effect was seen for platelet recovery (33.5 days vs 23.5 days). This may relate to a lower administered median CD34 + cell dose for these procedures (2.46 vs 4.00 × 10 6 /kg); administered total mononuclear cell (MNC) dose was not recorded as part of the audit.
Median time to ANC and platelet recovery was calculated for each of the 13 centres (Figure 1 ). For ANC recovery, the range of median values for each centre was 11-13.5 days. Two centres (K/L) had median ANC engraftment times of 13.5 days. This just reaches statistical significance for centre L when compared to the median for remaining centres, once adjusted for multiple comparisons (adjusted threshold for significance, P o0.004): for centre K vs other centres (excluding K/L), P = 0.0226; for centre L vs other centres (excluding K/L), P = 0.0024. The small absolute difference in recovery time is unlikely to be of clinical significance, but may relate to increased use of BMDSC at centre L (21% of procedures) compared to elsewhere (1.5%, P = 0.0001). Values for median platelet recovery had a wider range (14-31 days, overall median 24 days). There were no centres with significantly longer median recovery times than others.
This retrospective audit provides a snapshot of pediatric autograft activity in England and important data about the number and nature of procedures being undertaken. High-risk neuroblastoma patients receiving BuMel make up the largest single group and this is also the group with the strongest evidence base to support the benefit of HDC. 4, 5 By contrast, there was much more variation in practice for patients with CNS malignancies, reflecting a shortage of good quality randomised data to demonstrate the benefit of any particular HDC combination in these diseases and lack of open clinical trials in the UK during this period. The need for good quality randomised trials and careful monitoring of autograft clinical practice and outcomes is further emphasised by the reported UK experience of the Milan strategy for high-risk medulloblastoma with a failure to replicate the improved survival outcomes of the original study and concerns about additional neurotoxicity. 6, 7 Abbreviations: ATRT = atypical teratoid rhabdoid tumour; BEAM = carmustine/etoposide/cytarabine/melphalan; bu = busulfan; BuMel = busulfan/melphalan; carbo = carboplatin; CEM = carboplatin, etoposide, melphalan; cis = cisplatin; etop = etoposide; LEAM = lomustine/etoposide/cytarabine/melphalan; mIBG = 131 I-mIBG ± topotecan; PIE = cisplatin/ifosfamide/etoposide; topo = topotecan; TreoMel = treosulfan/melphalan. Others: clear cell sarcoma treated with thio/topo/carbo; extracranial rhabdoid tumour (carbo/thio); retinoblastoma (carbo/thio); acute promyelocytic leukaemia (bu/cyclo); T-ALL and Langerhans cell sarcoma (fludarabine/thio); dual lineage leukaemia (TBR plus cyclo). 
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The audit also provides quality assurance that there were no centres with unusually prolonged engraftment times. Although going forward, it will be a requirement for all English centres undertaking pediatric autografts to be accredited by JACIE, 8 this has not historically been the case. As of August 2015, eight PTCs had pediatric JACIE accreditation, four adult-only accreditation and one was not accredited. In the light of the experience at GOSH, 1 it was important to ensure that no other centres were or are experiencing similar problems. This audit provides reassurance that median engraftment times are broadly equivalent at all English PTCs. The median ANC recovery time at two centres of 13.5 days (vs overall median 12 days) is of borderline statistical significance and unlikely to be clinically important. As part of future national governance procedures for pediatric autografts, a continuing audit of engraftment data is planned. In addition, the NPAP is developing a list of indications for autografts in the pediatric cancer setting. An annual national meeting is planned to review autograft outcomes and to provide a means of oversight for unexpected toxicities and for future standardisation of apheresis procedures, autograft supportive care and infection prophylaxis. In combination with the responsibilities placed on individual centres as part of JACIE accreditation, it is anticipated that this will tighten governance ensuring that any future problems at an individual centre, or related to a specific nontrial protocol, are identified and addressed early.
In conclusion: /L independent of platelet support (minimum 7 days from transfusion).
